Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Go back to Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication| (NASDAQ: OCGN) | Delayed: 1.43 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.43 | 52 Week High | $ | |||
| Open | $1.43 | 52 Week Low | $ | |||
| Day High | $1.43 | P/E | N/A | |||
| Day Low | $1.43 | EPS | $ | |||
| Volume | 1,703 | |||||
